Patents by Inventor Chad Michael MAY

Chad Michael MAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20240261423
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: December 4, 2023
    Publication date: August 8, 2024
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20240199744
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: April 6, 2022
    Publication date: June 20, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Chad Michael May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20240181071
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: October 23, 2023
    Publication date: June 6, 2024
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20240156977
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 16, 2024
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20240026011
    Abstract: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 25, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia Culp, Chad Michael May, Danielle Dettling, Jeremiah Degenhardt
  • Anti-EDB antibodies and antibody-drug conjugates
    Patent number: 11833216
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: December 5, 2023
    Assignee: Pfizer Inc.
    Inventors: Andrea Therese Hooper, Kimberly Ann Marquette, Chakrapani Subramanyam, Hans-Peter Gerber, Chad Michael May
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20230340159
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia A. Culp, Chad Michael May, Danielle Dettling, Jeremiah Daniel Degenhardt
  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20230241235
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 3, 2023
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20190269791
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: October 3, 2017
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20180155452
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 7, 2018
    Applicant: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Bispecific heterodimeric diabodies and uses thereof
    Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20160002357
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: June 26, 2015
    Publication date: January 7, 2016
    Applicant: PFIZER INC.
    Inventors: Chad Michael MAY, Adam Reid ROOT, William A. BRADY, Lioudmila Gennadievna TCHISTIAKOVA, Lidia MOSYAK, Laird BLOOM, Paul A. MOORE, Leslie S. JOHNSON